Merck & Company, Inc.
MRKDrug Manufacturers - General
$146.33+3.83%As of Oct 29vs prior close
- Market cap
- $361B
- P/E (TTM)
- 115.2×
- P/E (FY1)
- 55.2×
- From 52W high
- −5.92%
- EPS (LTM)
- $1.25
- Revenue (LTM)
- $66.6B
- Net margin
- 4.77%
- Dividend yield
- 2.32%
Nomior Score
67
Steady ProfileTop 13% of the scored universe
Growth42
Quality69
Value49
Momentum96
Resilience48
Growth
+5.60%revenue a year over 9 fiscal years
FY16 $39.8BLTM $66.6B
Connections
Revenue to profitQ2 FY26
The operating loss was 1% of revenue, wider by 35 pts on a year.
Latest resultsthird quarter of 2026
- Adjusted EPS
- $2.49
Sales grew, led by oncology, Animal Health and WINREVAIR, while GAAP and non-GAAP profit declined as higher operating expenses, amortization and net interest expense weighed on results. Charges tied to a license agreement with SciBrunch also reduced earnings for the period. The company narrowed and raised its full-year sales and non-GAAP EPS outlook.
Who owns it
7funds, 9 tracked portfolios